338 Comparison of lymphodepleting chemotherapy regimens as preconditioning for T-cell therapies
Main Authors: | Stefan Zajic, Oleg Demin, Galina Kolesova, Natalia Ramos-Hernandez, Thomas Faitg, Lourdes Cucurull-Sanchez |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
354 Optimization of dose and regimen of letetresgene autoleucel for the treatment of synovial sarcoma: simulation of dose dependence and split dosing using quantitative systems pharmacology modeling
by: Stefan Zajic, et al.
Published: (2023-11-01) -
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
by: Ronnie Shapira-Frommer, et al.
Published: (2021-05-01) -
Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
by: Dimitrios Filioglou, et al.
Published: (2023-11-01) -
Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
by: Benno Lickefett, et al.
Published: (2023-12-01) -
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
by: Carter M. Suryadevara, et al.
Published: (2018-06-01)